<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="59">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 08, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01053013</url>
  </required_header>
  <id_info>
    <org_study_id>0911010739</org_study_id>
    <nct_id>NCT01053013</nct_id>
  </id_info>
  <brief_title>Open-Label Phase 2 Efficacy Trial of Cancer Macrobeads in Patients With Treatment-Resistant Pancreatic or Colorectal Cancer</brief_title>
  <acronym>Macrobead</acronym>
  <official_title>An Open-Label Phase 2 Efficacy Trial of the Implantation of Mouse Renal Adenocarcinoma Cell-Containing Agarose-Agarose Macrobeads in the Treatment of Patients With Treatment-Resistant, Metastatic Pancreatic or Colorectal Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Rogosin Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Rogosin Institute</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a clinical research study of an investigational (FDA IND-BB 10091) treatment for
      patients with pancreatic cancer (all stages) and advanced colorectal cancer that no longer
      responds to standard therapies.

      The treatment is being evaluated for its effect on tumor growth.  It consists of the
      placement (implantation) of small beads that contain mouse renal adenocarcinoma cells (RENCA
      macrobeads).   The cells in the macrobeads produce substances that have been shown to slow
      or stop the growth of tumors in experimental animals and veterinary patients.  It has been
      tested in 31 human subjects with different types of cancers in a Phase I safety trial.
      Phase II studies in patients with colorectal, pancreatic or prostate cancers are in
      progress.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2010</start_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Tumor volume and number of metastases</measure>
    <time_frame>16 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>16 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Pancreatic Cancer</condition>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Cancer macrobeads</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cancer macrobead placement in abdominal cavity</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cancer macrobead placement in abdominal cavity</intervention_name>
    <description>8 macrobeads per kilogram</description>
    <arm_group_label>Cancer macrobeads</arm_group_label>
    <other_name>cancer macrobeads</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cancer of pancreas, colon or rectum

          -  Evidence of metastasis

          -  Failed available therapies (pancreatic cancer may be treated without previous
             therapies)

          -  Resolution of any toxic effects of previous therapies

          -  Performance status (ECOG PS) 0-2

          -  Adequate hematologic, coagulation (INR 2-3 max), hepatic and renal function

          -  Life expectancy of at least 6 weeks

          -  For females, a negative pregnancy test

          -  Agrees to contraceptive use while on study if sexually active

          -  Informed consent

        Exclusion Criteria:

          -  Any condition presenting an unacceptably high anesthetic or surgical risk

          -  HIV positive

          -  Cognitive impairment such as to preclude informed consent

          -  Surgical treatment or chemotherapy within three weeks of scheduled macrobead
             implantation or   within four weeks of bevacizumab (or similar drugs), or radiation
             therapy within four weeks of scheduled macrobead implantation

          -  Inadequate hematologic, coagulation (INR &gt;3), hepatic, renal function

          -  Hepatic blood flow abnormalities and/or large-volume ascites

          -  Concurrent cancer of any other type except skin cancer (excluding melanoma)

          -  History of allergic reactions to mouse antigens

          -  Active infection, congestive heart failure, unstable angina, serious cardiac
             arrhythmias, psychiatric illness, difficult social situations not permitting reliable
             participation, active bleeding
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barry H Smith, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Rogosin Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Barry H Smith, MD, PhD</last_name>
    <phone>212-746-1551</phone>
    <email>bas2005@nyp.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nathaniel Berman, MD</last_name>
    <phone>212-746-9766</phone>
    <email>nab2009@nyp.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Rogosin Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barry H Smith, MD, PhD</last_name>
      <phone>212-746-1551</phone>
      <email>bas2005@nyp.org</email>
    </contact>
    <contact_backup>
      <last_name>Nathaniel Berman, MD</last_name>
      <phone>212-746-9766</phone>
      <email>nab2009@nyp.org</email>
    </contact_backup>
    <investigator>
      <last_name>Barry H Smith, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nathaniel Berman, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Allyson Ocean, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://rogosin.org/cancer</url>
    <description>http://rogosin.org/medical-research-education/medical-research-education-cancer.php</description>
  </link>
  <verification_date>June 2015</verification_date>
  <lastchanged_date>June 10, 2015</lastchanged_date>
  <firstreceived_date>January 20, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>macrobead</keyword>
  <keyword>biological</keyword>
  <keyword>mouse cells</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
